Johnson & Johnson (NYSE:JNJ) is Great West Life Assurance Co. Can’s 5th Largest Position

Great West Life Assurance Co. Can increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,294,564 shares of the company’s stock after acquiring an additional 1,993 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Great West Life Assurance Co. Can’s portfolio, making the stock its 5th biggest position. Great West Life Assurance Co. Can’s holdings in Johnson & Johnson were worth $538,321,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $39,000. Cardinal Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ opened at $168.74 on Monday. The stock has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock’s 50-day simple moving average is $176.14 and its two-hundred day simple moving average is $171.20. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.68%. Johnson & Johnson’s payout ratio is 62.95%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Credit Suisse Group initiated coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. StockNews.com started coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Citigroup increased their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.